VCM
ALLO icon

Voleon Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Voleon Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
485,621
-154,977
-24% -$340K 0.02% 473
2026
Q1 		$1.56M Buy
+640,598
New +$1.28M 0.03% 370

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Voleon Capital Management's ALLO Position: Q2 2026 in Review

Voleon Capital Management reduced its Allogene Therapeutics (ALLO) stake by 24% in Q2 2026, selling an estimated $340K and leaving 485,621 shares worth $1.01M. The position accounts for 0.02% of the portfolio, ranked #473.

Voleon Capital Management first reported a position in ALLO in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.56M in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Voleon Capital Management held 485,621 shares of Allogene Therapeutics worth $1.01M as of Q2 2026.
  • Voleon Capital Management sold 154,977 Allogene Therapeutics shares in Q2 2026, an estimated $340K.
  • Allogene Therapeutics made up 0.02% of Voleon Capital Management's portfolio in Q2 2026, its #473 holding.
  • Voleon Capital Management first reported a position in Allogene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Voleon Capital Management's Allogene Therapeutics position peaked at $1.56M in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.